Please assess the completion status of the following clinical trial:

Trial Title: Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* After a restaging TURBT patients with histologically proven primary high grade (grade3) and/or pT1 transitional cell carcinoma of the bladder, with or without pTis and pTis alone are regarded as being at high risk for tumour recurrence and progression.~* Patients may enroll in this study if they are thought to have no residual disease after TURBT.~* Age 18 years or over~* Adequate bone-marrow reserve- ECOG performance status between 0 and 2~* Patients who are known PPD positive will be screened for active tuberculosis prior to starting treatment with BCG.~Exclusion Criteria:~* known allergy to BCG or MMC~* prior systemic infection with BCG~* prior or concomitant urothelial tumours of the upper urinary tract or urethra~* previous muscle-invasive (ie, stage T2 or higher) transitional-cell carcinoma of the bladder~* bladder capacity of less than 200 ml~* untreated urinary-tract infection~* severe systemic infection (ie, sepsis)~* known HIV-positivity; therapy with immunosuppressive agents~* urethral strictures that would prevent endoscopic procedures and repeated catheterisation~* upper urinary tract disease (eg, vesicoureteral reflux or urinary-tract stones) that would make multiple transurethral procedures a risk~* previous radiotherapy to the pelvis~* other concurrent chemotherapy~* treatment with radiotherapy-response or biological-response modifiers~* history of tuberculosis;~* other malignant diseases within 5 years of trial registration (except for adequately treated basal-cell or squamous cell skin cancer, in situ cervical cancer and any other cancer from which patients has been disease-free for 3 years);~* pregnancy or nursing~* psychological, familial, sociological, or geographical factors that would preclude study participation.~* Patients with implantable or wearable electrical devices will be excluded from this study.~* Patients with active tuberculosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Intravesical BCG and EMDA/MMC (Type: EXPERIMENTAL): Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC

Based on this trial design, predict the completion outcome and termination type (if applicable).